NO961841D0 - Antitrombotiske amidinofenylalanin- og amidinopyridylalaninderivater - Google Patents

Antitrombotiske amidinofenylalanin- og amidinopyridylalaninderivater

Info

Publication number
NO961841D0
NO961841D0 NO961841A NO961841A NO961841D0 NO 961841 D0 NO961841 D0 NO 961841D0 NO 961841 A NO961841 A NO 961841A NO 961841 A NO961841 A NO 961841A NO 961841 D0 NO961841 D0 NO 961841D0
Authority
NO
Norway
Prior art keywords
conr5r6
pct
optionally substituted
alkyl
nr5r6
Prior art date
Application number
NO961841A
Other languages
English (en)
Norwegian (no)
Other versions
NO961841L (no
Inventor
John Christopher Danilewicz
David Ellis
Ryszard Jurek Kobylecki
Original Assignee
Pfizer Res & Dev
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Res & Dev filed Critical Pfizer Res & Dev
Publication of NO961841L publication Critical patent/NO961841L/no
Publication of NO961841D0 publication Critical patent/NO961841D0/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Materials For Medical Uses (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Treating Waste Gases (AREA)
  • Polyurethanes Or Polyureas (AREA)
  • Steroid Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
NO961841A 1993-11-08 1996-05-07 Antitrombotiske amidinofenylalanin- og amidinopyridylalaninderivater NO961841D0 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB939322976A GB9322976D0 (en) 1993-11-08 1993-11-08 Therapeutic agents
PCT/EP1994/003509 WO1995013274A1 (en) 1993-11-08 1994-10-24 Antithrombotic amidinophenylalanine and amidinopyridylalanine derivatives

Publications (2)

Publication Number Publication Date
NO961841L NO961841L (no) 1996-05-07
NO961841D0 true NO961841D0 (no) 1996-05-07

Family

ID=10744811

Family Applications (1)

Application Number Title Priority Date Filing Date
NO961841A NO961841D0 (no) 1993-11-08 1996-05-07 Antitrombotiske amidinofenylalanin- og amidinopyridylalaninderivater

Country Status (25)

Country Link
US (2) US5750520A (de)
EP (1) EP0728132B1 (de)
JP (1) JP2739776B2 (de)
KR (1) KR960705807A (de)
CN (1) CN1134148A (de)
AT (1) ATE155464T1 (de)
AU (1) AU680565B2 (de)
CA (1) CA2176037C (de)
CO (1) CO4290420A1 (de)
CZ (1) CZ282359B6 (de)
DE (1) DE69404325T2 (de)
DK (1) DK0728132T3 (de)
ES (1) ES2105868T3 (de)
FI (1) FI112481B (de)
GB (1) GB9322976D0 (de)
GR (1) GR3024228T3 (de)
HU (1) HUT76268A (de)
IL (1) IL111478A0 (de)
NO (1) NO961841D0 (de)
NZ (1) NZ275798A (de)
PE (1) PE22795A1 (de)
PL (1) PL314237A1 (de)
SG (1) SG52218A1 (de)
WO (1) WO1995013274A1 (de)
ZA (1) ZA948772B (de)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9522495D0 (en) * 1995-11-02 1996-01-03 Pfizer Ltd Therapeutic agents
US7109326B2 (en) 1997-04-15 2006-09-19 Genentech, Inc. Halo-alkoxycarbonyl prodrugs
IL123986A (en) 1997-04-24 2011-10-31 Organon Nv Medicinal compounds
US6740682B2 (en) 1997-08-29 2004-05-25 Tularik Limited Meta-benzamidine derivatives as serine protease inhibitors
DE69819349T2 (de) * 1997-08-29 2004-07-22 Tularik Ltd. 1-amino-7-isochinolin-derivate als serin protease inhibitoren
EP1023269A4 (de) * 1997-09-30 2001-06-27 Molecular Design Int Beta3-adrenoreceptor-agonisten, agonist-zubereitungen und verfahren zu ihrer verwendung
DK0997474T3 (da) 1998-08-14 2004-02-09 Pfizer Antithrombotiske midler
CA2408913A1 (en) 2000-05-16 2001-11-22 Takeda Chemical Industries, Ltd. Melanin-concentrating hormone antagonist
SI20743A (sl) 2000-12-22 2002-06-30 Univerza V Ljubljani, Novi trombinski inhibitorji
US6593341B2 (en) 2001-03-29 2003-07-15 Molecular Design International, Inc. β3-adrenoreceptor agonists, agonist compositions and methods of making and using the same
SI21137A (sl) * 2002-01-24 2003-08-31 LEK, tovarna farmacevtskih in kemičnih izdelkov, d.d. Derivati azafenilalanina
US6953787B2 (en) 2002-04-12 2005-10-11 Arena Pharmaceuticals, Inc. 5HT2C receptor modulators
PL374971A1 (en) * 2002-08-09 2005-11-14 Transtech Pharma, Inc. Aryl and heteroaryl compounds and methods to modulate coagulation
US6596734B1 (en) 2002-10-11 2003-07-22 Molecular Design International, Inc. Tetrahydroisoquinoline compounds for use as β3-adrenoreceptor agonists
EP2332920A3 (de) * 2003-06-17 2011-12-21 Arena Pharmaceuticals, Inc. Verfahren zur Herstellung von 3-Benzazepinen
EA016485B1 (ru) * 2003-06-17 2012-05-30 Арена Фармасьютикалз, Инк. Способы получения 3-бензазепинов
US7208601B2 (en) * 2003-08-08 2007-04-24 Mjalli Adnan M M Aryl and heteroaryl compounds, compositions, and methods of use
WO2005014532A1 (en) * 2003-08-08 2005-02-17 Transtech Pharma, Inc. Aryl and heteroaryl compounds, compositions and methods of use
CA2531796A1 (en) * 2003-08-08 2005-02-17 Transtech Pharma, Inc. Aryl and heteroaryl compounds, compositions, and methods of use
WO2005042490A1 (en) * 2003-10-22 2005-05-12 Arena Pharmaceuticals, Inc. Benzazepine derivatives and methods of prophylaxis or treatment of 5ht2c receptor associated diseases
WO2005042491A1 (en) * 2003-10-22 2005-05-12 Arena Pharmaceuticals, Inc. Benzazepine derivatives and methods of prophylaxis or treatment of 5ht2c receptor associated diseases
CN102321023A (zh) 2004-12-21 2012-01-18 艾尼纳制药公司 (r)-8-氯-1-甲基-2,3,4,5-四氢-1h-3-苯并氮杂卓盐酸盐的晶型
EA201100129A1 (ru) * 2004-12-23 2011-10-31 Арена Фармасьютикалз, Инк. Композиции и способы применения модулятора рецептора 5ht-2c
GB0507577D0 (en) 2005-04-14 2005-05-18 Novartis Ag Organic compounds
GB0523539D0 (en) * 2005-11-18 2005-12-28 Lek Tovarna Farmacevtskih New use of organic compounds
EP2518053A1 (de) * 2006-04-03 2012-10-31 Arena Pharmaceuticals, Inc. Verfahren zur Herstellung von 8-Chlor-1-Methyl-2,3,4,5-Tetrahydro-1H-3-Benzazepin
TWI389899B (zh) * 2006-08-08 2013-03-21 Msd Oss Bv 具口服活性之凝血酶抑制劑
JP5404414B2 (ja) * 2006-12-05 2014-01-29 アリーナ ファーマシューティカルズ， インコーポレイテッド （ｒ）−８−クロロ−１−メチル−２，３，４，５−テトラヒドロ−１ｈ−３−ベンゾアゼピンおよびその中間体を調製するための方法
EP2280964B1 (de) * 2008-02-21 2012-08-29 Sanofi Chlorthiophenisoxazole als inhibitoren von koagulationsfaktor xa und thrombin
DK2254881T3 (da) * 2008-02-21 2012-12-10 Sanofi Sa Chlorothiophenamides som inhibitorer af koagulationsfaktorerne xa og thrombin
JP5491421B2 (ja) * 2008-03-04 2014-05-14 アリーナ ファーマシューティカルズ， インコーポレイテッド ５−ｈｔ２ｃアゴニストである（ｒ）−８−クロロ−１−メチル−２，３，４，５−テトラヒドロ−１ｈ−３−ベンゾアゼピンに関連する中間体の調製のためのプロセス
WO2010148207A2 (en) 2009-06-18 2010-12-23 Arena Pharmaceuticals, Inc. Processes for the preparation of 5-ht2c receptor agonists
AR080375A1 (es) 2010-03-05 2012-04-04 Sanofi Aventis Procedimiento para la preparacion de 2-(cicloheximetil)-n-{2-[(2s)-1-metilpirrolidin-2-il] etil}-1,2,3,4-tetrahidroisoquinolina- 7-sulfonamida
KR20130112848A (ko) 2010-06-02 2013-10-14 아레나 파마슈티칼스, 인크. 5-ｈｔ2ｃ 수용체 아고니스트의 제조 방법
EP2939677A1 (de) 2010-09-01 2015-11-04 Arena Pharmaceuticals, Inc. Verabreichung von lorcaserin an personen mit nierenerkrankungen
WO2012030938A1 (en) 2010-09-01 2012-03-08 Arena Pharmaceuticals, Inc. Salts of lorcaserin with optically active acids
KR20130101524A (ko) 2010-09-01 2013-09-13 아레나 파마슈티칼스, 인크. 5-ｈｔ2ｃ 아고니스트의 비-흡습성 염
AU2011296003B2 (en) 2010-09-01 2015-11-12 Arena Pharmaceuticals, Inc. Modified-release dosage forms of 5-HT2C agonist useful for weight management
KR20190128001A (ko) 2012-10-09 2019-11-13 에자이 알앤드디 매니지먼트 가부시키가이샤 체중 관리 방법
WO2018213150A1 (en) 2017-05-15 2018-11-22 Mitobridge, Inc. Usp30 inhibitors

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH05503300A (ja) * 1990-11-15 1993-06-03 ペンタファルム　アクチェンゲゼルシャフト メタ置換フェニルアラニン誘導体

Also Published As

Publication number Publication date
JPH09500391A (ja) 1997-01-14
IL111478A0 (en) 1994-12-29
CZ132296A3 (en) 1996-08-14
NO961841L (no) 1996-05-07
ES2105868T3 (es) 1997-10-16
KR960705807A (ko) 1996-11-08
JP2739776B2 (ja) 1998-04-15
CO4290420A1 (es) 1996-04-17
GB9322976D0 (en) 1994-01-05
SG52218A1 (en) 1998-09-28
CA2176037A1 (en) 1995-05-18
GR3024228T3 (en) 1997-10-31
PE22795A1 (es) 1995-08-15
HU9601229D0 (en) 1996-07-29
PL314237A1 (en) 1996-09-02
FI961939A (fi) 1996-05-07
CA2176037C (en) 1999-07-13
CZ282359B6 (cs) 1997-07-16
HUT76268A (en) 1997-07-28
FI961939A0 (fi) 1996-05-07
EP0728132B1 (de) 1997-07-16
AU680565B2 (en) 1997-07-31
US5861393A (en) 1999-01-19
US5750520A (en) 1998-05-12
DE69404325D1 (de) 1997-08-21
ATE155464T1 (de) 1997-08-15
ZA948772B (en) 1996-05-07
AU8104994A (en) 1995-05-29
NZ275798A (en) 1997-09-22
EP0728132A1 (de) 1996-08-28
WO1995013274A1 (en) 1995-05-18
DE69404325T2 (de) 1997-10-30
CN1134148A (zh) 1996-10-23
FI112481B (fi) 2003-12-15
DK0728132T3 (da) 1997-09-01

Similar Documents

Publication Publication Date Title
DE69404325D1 (de) Antithrombotische amidinophenylalanin- und amidinopyridylalanin-derivate
GR3033070T3 (en) Antithrombotic amidinotetrahydropyridylalanine derivatives
DE60221391D1 (de) Substituierte indolsäurederivate als inhibitoren von plasminogen-aktivator-inhibitor-1 (pai-1)
WO2004052893A3 (en) Substituted dihydropyrano indole-3,4-dione derivatives and 3-oxoacetic acid substituted 2-hydroxymethylindole derivatives as inhibitors of plasminogen activator inhibitor-1 (pai-1)
WO2004052854A3 (en) Aryl, aryloxy, and alkyloxy substituted 1h-indol-3-yl glyoxylic acid derivatives as inhibitors of plasminogen activator inhibitor-1 (pai-1)
MXPA03011400A (es) Derivados de naftil benzofurano como inhibidores del inhibidor-1de activador de plasminogeno (pai-1).
WO2005042533A3 (en) 2-cyanopyrrolidinecarboxamides as dipeptidyl peptidase-iv inhibitors
SE9602646D0 (sv) Pharmaceutically-useful compounds
ATE331709T1 (de) Substituierte 3-carbonyl-1-yl essigsäure derivate als plasminogen aktivator inhibitor(pai-1) inhibitoren
NO983992L (no) Serinprotease inhibitorer
ATE407116T1 (de) Neue amidino-derivate und deren verwendung als thrombin-inhibitoren
MX9708278A (es) Derivados de amidinotetrahidropiridilalanina, procedimiento para su preparacion y uso de los mismos.
MX9803498A (es) Derivados de n-amidino piperidina y benzamidina antitromboticos.
RS20050514A (en) Compounds having prolyl oligopeptidase inhibitory activity
EA200300059A1 (ru) Комбинированная противоопухолевая терапия, включающая применение производных замещенного акрилоилдистамицина, таксанов и/или антиметаболитов
ECSP961723A (es) Derivados de amidinotetrahidropiridilalanina antitromboticos
KR950700897A (ko) 옥소-및 히드록시-치환된 탄화수소의 아민 유도체(Amine Derivatives of oxo- and hydroxy-substituted hydrocarbons)